

## Declaration of Interests Register

**TA Committee A**

**Publication Date: 03/02/2021**

**Topic: Brolucizumab for treating wet age-related macular degeneration [ID1254]**

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Becky Pennington	TAC A Committee Member	Non-Financial Personal Interest	Becky has co-authored conference abstracts (published) and an HTA report (accepted but not yet published) and is working on journal manuscripts reporting a cost-effectiveness analysis of bevacizumab, aflibercept and ranibizumab in macular oedema. Funding for the research was provided by NIHR and has ended, but this work expresses the finding that bevacizumab is cost-effective.	N/A	19.10.2020	N/A	It was agreed before the meeting that this declaration would not prevent Becky from participating in discussions on this topic. Becky verbally declared her interest in the meeting.